{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.7422","value":"3.198"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"141"}],"units":"Participants"}],"title":"Mirvetuximab soravtansine at Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.022","value":"3.172"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"87"}],"units":"Participants"}],"title":"Mirvetuximab soravtansine at Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.9183","value":"3.744"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"141"}],"units":"Participants"}],"title":"Total M9346A antibody at Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.185","value":"3.671"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"87"}],"units":"Participants"}],"title":"Total M9346A antibody at Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"38770","value":"107400"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"}],"units":"Participants"}],"title":"DM4 at Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"48740","value":"114300"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"}],"units":"Participants"}],"title":"DM4 at Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27890","value":"41590"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"}],"units":"Participants"}],"title":"S-methyl DM4 at Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"40440","value":"47520"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"}],"units":"Participants"}],"title":"S-methyl DM4 at Cycle 3"}],"denoms":[{"counts":[{"groupId":"OG000","value":"142"}],"units":"Participants"}],"description":"PK parameters were calculated using standard non-compartmental methods. PK analysis of mirvetuximab soravtansine, free DM4, S-methyl DM4, and total M9346A antibody is presented for a subgroup of participants who received 6.0 mg/kg (RP2D) mirvetuximab soravtansine at Cycle 1 and Cycle 3.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received mirvetuximab soravtansine 6.0 mg/kg (calculated based on AIBW) on Day 1 of Cycle 1 and Cycle 3.","id":"OG000","title":"Mirvetuximab Soravtansine 6.0 mg/kg AIBW"}],"paramType":"MEAN","populationDescription":"PK Population included all participants who received at least 1 infusion of mirvetuximab soravtansine and had evaluable PK data. 'Overall number of participants analyzed' = participants who received mirvetuximab soravtansine at 6 mg/kg AIBW. 'Number analyzed' = participants evaluable for this outcome for specified categories.","reportingStatus":"POSTED","timeFrame":"Cycle 1, 3: Day 1 (pre-infusion; within 10 min of EOI; 2, 4, 6, 8 hrs post-infusion); Day 2, 3 (24, 48 hrs post-infusion); Day 4 or 5, 8, 15 (24 hrs post-infusion)","title":"Volume of Distribution at Steady State (Vss) of Mirvetuximab Soravtansine Free DM4, S-Methyl DM4, and Total M9346A Antibody at RP2D","type":"SECONDARY","unitOfMeasure":"Liters"}